医学
特发性肺纤维化
临床试验
任天堂
吡非尼酮
内科学
重症监护医学
药物开发
肺纤维化
药品
间质性肺病
疾病
药物治疗
不利影响
临床研究
作者
Giacomo Sgalla,Marialessia Lerede,Luca Richeldi
标识
DOI:10.1080/14728214.2021.1931119
摘要
The enthusiasm generated by the approval of pirfenidone and nintedanib as the first effective therapies for IPF led the IPF scientific community to investigate an increasing number of novel agents ...
科研通智能强力驱动
Strongly Powered by AbleSci AI